Aisling Capital buys $12,121,027 stake in Cidara Therapeutics Inc (CDTX)

Cidara Therapeutics Inc (CDTX) : Aisling Capital scooped up 1,693 additional shares in Cidara Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 1,021,148 shares of Cidara Therapeutics Inc which is valued at $12,121,027.Cidara Therapeutics Inc makes up approximately 2.60% of Aisling Capital’s portfolio.

Other Hedge Funds, Including , Tekla Capital Management boosted its stake in CDTX in the latest quarter, The investment management firm added 59,972 additional shares and now holds a total of 132,472 shares of Cidara Therapeutics Inc which is valued at $1,572,443. Cidara Therapeutics Inc makes up approx 0.06% of Tekla Capital Management’s portfolio.Teachers Advisors Inc boosted its stake in CDTX in the latest quarter, The investment management firm added 7,137 additional shares and now holds a total of 14,066 shares of Cidara Therapeutics Inc which is valued at $166,963.Tiaa Cref Investment Management boosted its stake in CDTX in the latest quarter, The investment management firm added 24,128 additional shares and now holds a total of 39,516 shares of Cidara Therapeutics Inc which is valued at $469,055.Blackrock Japan Ltd reduced its stake in CDTX by selling 252 shares or 20.18% in the most recent quarter. The Hedge Fund company now holds 997 shares of CDTX which is valued at $11,834.Strs Ohio boosted its stake in CDTX in the latest quarter, The investment management firm added 4,500 additional shares and now holds a total of 6,000 shares of Cidara Therapeutics Inc which is valued at $71,100.

Cidara Therapeutics Inc opened for trading at $11 and hit $11.39 on the upside on Monday, eventually ending the session at $11.33, with a gain of 2.72% or 0.3 points. The heightened volatility saw the trading volume jump to 14,155 shares. Company has a market cap of $158 M.

Cidara Therapeutics Inc. formerly K2 Therapeutics Inc. is a biotechnology company. The Company is focused on the discovery development and commercialization of anti-infective products. The Company’s products are the formulations of its compound CD101 which is an echinocandin. Its products include CD101 intravenous (biafungin) and CD101 topical (topifungin). In addition it owns an immunotherapy technology platform Cloudbreak. The Company is also developing other candidates for the treatment of bacterial and viral infections. CD101 IV and CD101 topical are in early stage of preclinical development. The Company’s Cloudbreak development candidates includeC001 and C016. It has conducted preclinical studies to evaluate the tolerability toxicity and pharmacokinetic profile of C001 in mice and guinea pigs. Cloudbreak development candidates have demonstrated preclinical proof-of-principle efficacy and safety in preclinical studies.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *